कृपया अन्य खोज का प्रयास करें
Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Ulf Bjorklund | 66 | - | Independent Chairman of the Board |
Olle Hernell | 78 | - | Co-Founder & Director |
Ingemar Kihlstrom | 71 | 2021 | Independent Director |
Asa Hansdotter | 49 | 2021 | Independent Director |
Lennart Lundberg | 70 | 2021 | Member of Scientific Advisory Board |
Kristian Sandberg | 62 | 2020 | Independent Director |
Björn Löwenadler | 71 | - | Member of Scientific Advisory Board |
Carl-Johan Spak | 67 | 2023 | Independent Director |
Rikard Holmdahl | - | - | Member of Scientific Advisory Board |
Solbritt Rantapaa Dahlqvist | - | - | Member of Scientific Advisory Board |
Anders Fasth | - | - | Member of Scientific Advisory Board |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है